What is Zacks Small Cap’s Estimate for MIRA FY2024 Earnings?

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) – Research analysts at Zacks Small Cap cut their FY2024 EPS estimates for MIRA Pharmaceuticals in a note issued to investors on Tuesday, March 4th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of ($0.66) for the year, down from their previous forecast of ($0.60). The consensus estimate for MIRA Pharmaceuticals’ current full-year earnings is ($0.60) per share.

MIRA Pharmaceuticals Stock Performance

Shares of MIRA opened at $1.01 on Thursday. The business’s 50-day moving average is $1.16 and its two-hundred day moving average is $1.31. The company has a market capitalization of $16.73 million, a P/E ratio of -1.80 and a beta of 2.31. MIRA Pharmaceuticals has a fifty-two week low of $0.51 and a fifty-two week high of $5.01.

Institutional Trading of MIRA Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new stake in MIRA Pharmaceuticals during the fourth quarter valued at $112,000. Virtu Financial LLC acquired a new stake in shares of MIRA Pharmaceuticals during the 4th quarter valued at about $72,000. Renaissance Technologies LLC acquired a new position in MIRA Pharmaceuticals in the 4th quarter worth about $52,000. Northern Trust Corp raised its holdings in MIRA Pharmaceuticals by 50.9% in the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock worth $35,000 after purchasing an additional 10,238 shares during the period. Finally, International Assets Investment Management LLC purchased a new position in MIRA Pharmaceuticals during the fourth quarter worth approximately $29,000. 35.16% of the stock is owned by institutional investors and hedge funds.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.